A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm

被引：9

作者：

Roy, Arya Mariam ^{[1
]}

Kumarasamy, Vasanthan Muthusamy ^{[2
]}

Dhakal, Ajay ^{[3
]}

O'Regan, Ruth ^{[3
]}

Gandhi, Shipra ^{[1
,4
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY 14203 USA

[2] Univ Buffalo, Dept Med, Buffalo, NY USA

[3] Univ Rochester, Dept Med, Med Ctr, Rochester, NY USA

[4] Roswell Pk Comprehens Canc Ctr, Dept Hematol & Oncol, Buffalo, NY 14203 USA

来源：

CANCER | 2023年 / 129卷 / 18期

基金：

美国国家卫生研究院;

关键词：

alpelisib; everolimus; HER2-low breast cancer; hormone receptor negative HER2-low; hormone receptor-positive HER2-low; PARP inhibitors; sacituzumab govitecan; trastuzumab deruxtecan; ALPELISIB PLUS FULVESTRANT; SACITUZUMAB GOVITECAN; HER2-TARGETING ADC; OPEN-LABEL; EFFICACY; ANTIBODY; INHIBITOR; SURVIVAL; MULTICENTER; EVEROLIMUS;

D O I：

10.1002/cncr.34904

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)-status to HER2-low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. The HER2-low expression has emerged as a targetable biomarker, and anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer (BC). With these recent data, the treatment algorithm for hormone receptor-positive and triple-negative BC needs to be reconsidered, as approximately half of these BCs are HER2-low. Although there are different therapeutic agents for hormone receptor-positive and hormone receptor-negative HER2-low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2-low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed.

引用

页码：2773 / 2788

页数：16

共 65 条

[1] Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience [J].

Alaklabi, Sabah ;

Roy, Arya Mariam ;

Attwood, Kristopher ;

George, Anthony ;

O'Connor, Tracey ;

Early, Amy ;

Levine, Ellis G. ;

Gandhi, Shipra .

FRONTIERS IN ONCOLOGY, 2022, 12

[2] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].

Andre, F. ;

Ciruelos, E. M. ;

Juric, D. ;

Loibl, S. ;

Campone, M. ;

Mayer, I. A. ;

Rubovszky, G. ;

Yamashita, T. ;

Kaufman, B. ;

Lu, Y-S ;

Inoue, K. ;

Papai, Z. ;

Takahashi, M. ;

Ghaznawi, F. ;

Mills, D. ;

Kaper, M. ;

Miller, M. ;

Conte, P. F. ;

Iwata, H. ;

Rugo, H. S. .

ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217

[3] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[4] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[5] First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [J].

Bang, Y. J. ;

Giaccone, G. ;

Im, S. A. ;

Oh, D. Y. ;

Bauer, T. M. ;

Nordstrom, J. L. ;

Li, H. ;

Chichili, G. R. ;

Moore, P. A. ;

Hong, S. ;

Stewart, S. J. ;

Baughman, J. E. ;

Lechleider, R. J. ;

Burris, H. A. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :855-861

[6] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[7] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

[8] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial [J].

Bartsch, Rupert ;

Berghoff, Anna Sophie ;

Furtner, Julia ;

Marhold, Maximilian ;

Bergen, Elisabeth Sophie ;

Roider-Schur, Sophie ;

Starzer, Angelika Martina ;

Forstner, Heidrun ;

Rottenmanner, Beate ;

Dieckmann, Karin ;

Bago-Horvath, Zsuzsanna ;

Haslacher, Helmuth ;

Widhalm, Georg ;

Ilhan-Mutlu, Aysegul ;

Minichsdorfer, Christoph ;

Fuereder, Thorsten ;

Szekeres, Thomas ;

Oehler, Leopold ;

Gruenberger, Birgit ;

Singer, Christian F. ;

Weltermann, Ansgar ;

Puhr, Rainer ;

Preusser, Matthias .

NATURE MEDICINE, 2022, 28 (09) :1840-+

[9] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[10] Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas [J].

Berrino, Enrico ;

Annaratone, Laura ;

Bellomo, Sara Erika ;

Ferrero, Giulio ;

Gagliardi, Amedeo ;

Bragoni, Alberto ;

Grassini, Dora ;

Guarrera, Simonetta ;

Parlato, Caterina ;

Casorzo, Laura ;

Panero, Mara ;

Sarotto, Ivana ;

Giordano, Silvia ;

Cereda, Matteo ;

Montemurro, Filippo ;

Ponzone, Riccardo ;

Crosetto, Nicola ;

Naccarati, Alessio ;

Sapino, Anna ;

Marchio, Caterina .

GENOME MEDICINE, 2022, 14 (01) :98

← 1 2 3 4 5 6 7 →